Form 4: Marimed CEO Levine Converts RSUs, Covers Taxes

Marimed Inc.'s President and CEO, Jon R. Levine, reported the conversion of 75,000 Restricted Stock Units into common stock and the subsequent sale of 22,013 shares to cover tax obligations.

Summary

• Jon R. Levine, President and CEO, Director, and 10% Owner of Marimed Inc., reported transactions on November 7, 2025.
• Acquired 75,000 shares of common stock through the conversion of Restricted Stock Units (RSUs).
• Disposed of 22,013 shares of common stock at a price of $0.097 per share to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions, Levine directly beneficially owns 21,006,481 shares of common stock.
• Levine also indirectly beneficially owns 6,684,640 shares through the Jon Levine Family Trust, though he disclaims beneficial ownership of these securities.
• The RSUs converted were part of an award granted on November 7, 2023.
• An additional 150,000 RSUs are scheduled to vest in two equal installments on May 7, 2026, and November 7, 2026.

Sentiment

Score: 6

Explanation: The filing reports a routine insider transaction involving RSU vesting and tax-related share disposition. While the sale for taxes is a slight reduction in direct ownership, the overall event is a standard compensation mechanism and indicates continued executive alignment through significant remaining holdings. The future vesting schedule provides clarity on upcoming compensation events.

Positives

• Conversion of RSUs indicates a vesting event, which is a positive for the executive as it represents earned compensation.
• The executive continues to hold a significant direct and indirect stake in the company, demonstrating alignment with shareholder interests.

Negatives

• A portion of the shares (22,013) was sold to cover tax liabilities, which is a common practice but reduces the executive's direct ownership slightly.

Future Outlook

Remaining Restricted Stock Units (RSUs) totaling 150,000 shares are scheduled to vest in two equal installments on May 7, 2026, and November 7, 2026.

Management Comments

• The Reporting Person disclaims beneficial ownership of these securities [held by the Jon Levine Family Trust], and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Industry Context

This filing represents a routine insider transaction related to executive compensation and tax obligations, common across all industries for publicly traded companies. It does not provide specific insights into broader industry trends for the cannabis sector (Marimed's industry).

Related Party Transactions

• The indirect beneficial ownership of 6,684,640 shares held by the Jon Levine Family Trust is disclosed, with the reporting person disclaiming beneficial ownership. This is a standard disclosure for related party holdings.

Stakeholder Impact

• Shareholders: The transaction is a routine compensation event for a key executive. The executive maintains a substantial stake, which can be viewed positively for alignment of interests. The sale for tax purposes is a minor dilution relative to total shares outstanding.
• Employees: No direct impact on general employees.
• Customers/Suppliers/Creditors: No direct impact.

Next Steps

• Remaining 150,000 RSUs will vest in two equal installments on May 7, 2026, and November 7, 2026.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction where the CEO converted Restricted Stock Units into common stock and sold a portion to cover tax liabilities. Such transactions are standard compensation events and do not typically signal a change in the company's fundamental outlook or the executive's confidence. The CEO retains a substantial direct and indirect ownership stake, indicating continued alignment with shareholder interests. Therefore, based solely on this filing, a 'hold' recommendation is appropriate as it provides no new information to alter an existing investment thesis.

Keywords

Marimed Inc., MRMD, Jon R. Levine, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU Conversion, Stock Sale, Tax Withholding, Beneficial Ownership